Legend Biotech Corporation
LEGN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $627 | $285 | $117 | $69 |
| % Growth | 120% | 143.7% | 70% | – |
| Cost of Goods Sold | $235 | $144 | $65 | $0 |
| Gross Profit | $393 | $141 | $52 | $69 |
| % Margin | 62.6% | 49.4% | 44.1% | 100% |
| R&D Expenses | $414 | $382 | $336 | $313 |
| G&A Expenses | $137 | $107 | $81 | $47 |
| SG&A Expenses | $284 | $201 | $174 | $150 |
| Sales & Mktg Exp. | $147 | $94 | $93 | $103 |
| Other Operating Expenses | -$2 | -$3 | -$2 | -$2 |
| Operating Expenses | $696 | $580 | $507 | $461 |
| Operating Income | -$303 | -$439 | -$456 | -$392 |
| % Margin | -48.3% | -154.1% | -389.4% | -570% |
| Other Income/Exp. Net | $145 | -$81 | $10 | -$15 |
| Pre-Tax Income | -$158 | -$520 | -$446 | -$407 |
| Tax Expense | $19 | -$2 | $1 | -$4 |
| Net Income | -$177 | -$518 | -$446 | -$404 |
| % Margin | -28.2% | -181.8% | -381.5% | -586.4% |
| EPS | -1.94 | -5.88 | -5.62 | -5.48 |
| % Growth | 67% | -4.6% | -2.6% | – |
| EPS Diluted | -1.94 | -5.88 | -5.62 | -5.48 |
| Weighted Avg Shares Out | 91 | 88 | 80 | 70 |
| Weighted Avg Shares Out Dil | 91 | 88 | 80 | 70 |
| Supplemental Information | – | – | – | – |
| Interest Income | $61 | $54 | $8 | $1 |
| Interest Expense | $22 | $22 | $11 | $1 |
| Depreciation & Amortization | $23 | $20 | $18 | $14 |
| EBITDA | -$113 | -$478 | -$417 | -$392 |
| % Margin | -18% | -167.6% | -356% | -570.1% |